為達最佳瀏覽效果,建議使用 Chrome、Firefox 或 Microsoft Edge 的瀏覽器。

請至Edge官網下載 請至FireFox官網下載 請至Google官網下載
晴時多雲

限制級
您即將進入之新聞內容 需滿18歲 方可瀏覽。
根據「電腦網路內容分級處理辦法」修正條文第六條第三款規定,已於網站首頁或各該限制級網頁,依台灣網站分級推廣基金會規定作標示。 台灣網站分級推廣基金會(TICRF)網站:http://www.ticrf.org.tw

《TAIPEI TIMES》 Blood pressure medicines recalled due to impurities

A box of Vaks 160mg blood pressure tablets is pictured in an undated handout.
Photo provided by the Food and Drug Administration

A box of Vaks 160mg blood pressure tablets is pictured in an undated handout. Photo provided by the Food and Drug Administration

2019/02/17 03:00

SUPPLY CHAIN: Synmosa Biopharma’s Vaks tablets and Synpac-Kingdom’s Disartan 80mg were found to contain a cancer-causing ingredient from the same Chinese factory

/ Staff writer, with CNA

Two local pharmaceutical firms have issued recalls for blood pressure medication after their drugs were found to contain potential carcinogens, the Food and Drug Administration (FDA) said, following similar recalls worldwide.

Taipei-based Synmosa Biopharma Corp (健喬信元醫藥生技) on Friday informed the agency that during a self-screening it had discovered that the active ingredient valsartan in its Vaks 80mg and Vaks 160mg tablets contained N-nitrosodimethylamine (NDMA), a substance suspected to increase the likelihood of cancer, the FDA said in a statement

The valsartan came from Tianyu Pharmaceutical Co (天宇), in China’s Zhejiang Province, and had the batch number 10230-160509, the agency said.

The recall, which is to continue until June, affects about 660,000 million tablets produced by Synmosa in three batches, with the numbers B26541, B24691 and B22371, the agency said.

In addition, the FDA said it has found that Tianyu Pharmaceutical’s Valsartan was also used by Synpac-Kingdom Pharmaceutical Co (景德製藥), another Taiwanese pharmaceutical firm, to produce blood pressure medication.

The agency on Friday asked Synpac-Kingdom to recall its Disartan 80mg containing the ingredient, which would affect 577,000 tablets from two batches with the code numbers AGR098 and AGW118, it said.

The two firms aim to complete the recall by March 15, the FDA said.

The incident is the latest among several cases worldwide in which potentially tainted blood pressure medication has been recalled.

The US Food and Drug Administration in July and August last year announced recalls of blood pressure drugs containing valsartan that were contaminated with NDMA or a similar impurity, N-nitrosodiethylamine.

All of the recalled products had ingredients made in India or China.

FDA division head Hung Kuo-teng (洪國登) in December said that when the agency first heard of the potential problems in July, it began checking blood pressure drugs on the local market and asked drug makers to screen their own products for impurities.

The EU in summer and fall last year also launched global recalls of drugs after discovering that the valsartan they contained, which came from India, was contaminated, Hung said.

新聞來源:TAIPEI TIMES

%http://www.taipeitimes.com/

不用抽 不用搶 現在用APP看新聞 保證天天中獎  點我下載APP  按我看活動辦法

焦點今日熱門
看更多!請加入自由時報粉絲團

網友回應

載入中
此網頁已閒置超過5分鐘,請點擊透明黑底或右下角 X 鈕。